Follow
Hengyou Weng
Hengyou Weng
Verified email at coh.org
Title
Cited by
Cited by
Year
Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation
H Huang, H Weng, W Sun, X Qin, H Shi, H Wu, BS Zhao, A Mesquita, ...
Nature cell biology 20 (3), 285-295, 2018
19562018
FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase
Z Li, H Weng, R Su, X Weng, Z Zuo, C Li, H Huang, S Nachtergaele, ...
Cancer cell 31 (1), 127-141, 2017
12582017
R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling
R Su, L Dong, C Li, S Nachtergaele, M Wunderlich, Y Qing, X Deng, ...
Cell 172 (1), 90-105. e23, 2018
8552018
METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification
H Weng, H Huang, H Wu, X Qin, BS Zhao, L Dong, H Shi, J Skibbe, ...
Cell stem cell 22 (2), 191-205. e9, 2018
8202018
m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer
H Huang, H Weng, J Chen
Cancer cell 37 (3), 270-288, 2020
7692020
RNA N6-methyladenosine modification in cancers: current status and perspectives
X Deng, R Su, H Weng, H Huang, Z Li, J Chen
Cell research 28 (5), 507-517, 2018
5972018
Histone H3 trimethylation at lysine 36 guides m 6 A RNA modification co-transcriptionally
H Huang, H Weng, K Zhou, T Wu, BS Zhao, M Sun, Z Chen, X Deng, ...
Nature 567 (7748), 414-419, 2019
4952019
Targeting FTO suppresses cancer stem cell maintenance and immune evasion
R Su, L Dong, Y Li, M Gao, L Han, M Wunderlich, X Deng, H Li, Y Huang, ...
Cancer cell 38 (1), 79-96. e11, 2020
4442020
Roles of METTL3 in cancer: mechanisms and therapeutic targeting
C Zeng, W Huang, Y Li, H Weng
Journal of hematology & oncology 13 (1), 117, 2020
3052020
RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia
C Shen, Y Sheng, AC Zhu, S Robinson, X Jiang, L Dong, H Chen, R Su, ...
Cell stem cell 27 (1), 64-80. e9, 2020
2722020
The biogenesis and precise control of RNA m6A methylation
H Huang, H Weng, J Chen
Trends in Genetics 36 (1), 44-52, 2020
2102020
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia
X Jiang, C Hu, S Arnovitz, J Bugno, M Yu, Z Zuo, P Chen, H Huang, ...
Nature communications 7 (1), 11452, 2016
1392016
Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis
HL Huang, HY Weng, LQ Wang, CH Yu, QJ Huang, PP Zhao, JZ Wen, ...
Molecular cancer therapeutics 11 (5), 1155-1165, 2012
1042012
Attacking c-Myc: targeted and combined therapies for cancer
H Huang, H Weng, H Zhou, L Qu
Current pharmaceutical design 20 (42), 6543-6554, 2014
862014
Overexpression and knockout of miR-126 both promote leukemogenesis
Z Li, P Chen, R Su, Y Li, C Hu, Y Wang, S Arnovitz, M He, S Gurbuxani, ...
Blood, The Journal of the American Society of Hematology 126 (17), 2005-2015, 2015
822015
Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S
H Weng, H Huang, B Dong, P Zhao, H Zhou, L Qu
Cancer research 74 (16), 4409-4419, 2014
782014
PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease
Z Li, P Chen, R Su, C Hu, Y Li, AG Elkahloun, Z Zuo, S Gurbuxani, ...
Cancer research 76 (3), 619-629, 2016
772016
The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia
H Weng, F Huang, Z Yu, Z Chen, E Prince, Y Kang, K Zhou, W Li, J Hu, ...
Cancer Cell 40 (12), 1566-1582. e10, 2022
712022
RNA modifications in cancer: functions, mechanisms, and therapeutic implications
H Huang, H Weng, X Deng, J Chen
Annual Review of Cancer Biology 4, 221-240, 2020
702020
The pathological role and prognostic impact of miR-181 in acute myeloid leukemia
H Weng, K Lal, FF Yang, J Chen
Cancer genetics 208 (5), 225-229, 2015
692015
The system can't perform the operation now. Try again later.
Articles 1–20